Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790400 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
A Phase 3 study of Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 118
- Enrollment target
- 20
- Study locations
NCT00790400 is a Phase 3 study of Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 118 participants, above the 12-participant average among 3 other Lymphangioleiomyomatosis (LAM) trials with a reported enrollment target (883% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT00790400, a Phase 3 study of Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 118 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
Conditions Studied
Interventions
- DRUG Everolimus (RAD001)
- DRUG Everolimus Placebo
Study Locations (20)
Other
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - München
- Novartis Investigative Site - Roma
- Novartis Investigative Site - Warsaw
- Novartis Investigative Site - Warsaw
- Novartis Investigative Site - Moscow
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Barrow Tuberous Sclerosis Center - Phoenix
Massachusetts
- Massachusetts General Hospital Massachussetts General Hospita - Boston
Minnesota
- Minnesota Epilepsy Group - Saint Paul
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Tennessee
- LeBonheur Childrens Medical Group SC-2 - Memphis
Ontario
- Novartis Investigative Site - Torono
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2009-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790400
The ClinicalTrials.gov registry entry for NCT00790400 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 12-participant average among 3 other Lymphangioleiomyomatosis (LAM) trials with a reported enrollment target (883% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphangioleiomyomatosis (LAM) appearing as the primary indexed condition, and to 2 interventions - of which Everolimus (RAD001) is the first listed.
NCT00790400 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00790400 about?
NCT00790400 is a clinical study titled "Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)". This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
What is the current status of trial NCT00790400?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 118 participants. The study started on 2009-04. Estimated completion is 2015-11.
What conditions does trial NCT00790400 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis (LAM), Tuberous Sclerosis Complex (TSC).
What interventions are being tested in trial NCT00790400?
The interventions under investigation include: Everolimus (RAD001) (DRUG), Everolimus Placebo (DRUG).
Who is sponsoring clinical trial NCT00790400?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790400 being conducted?
This trial has 20 study locations across Alabama, Arizona, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis (LAM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Lymphangioleiomyomatosis (LAM)
All registered trials for this condition
Tuberous Sclerosis Complex (TSC)
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.